

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM531876

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
PERCEPTIVE CREDIT HOLDINGS, LP		07/15/2019	Corporation: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	AQUESTIVE THERAPEUTICS, INC.
<b>Street Address:</b>	30 Technology Drive
<b>City:</b>	Warren
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07059
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	MONOSOL RX, INC.
<b>Street Address:</b>	30 Technology Drive
<b>City:</b>	Warren
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07059
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	MSRX US, LLC
<b>Street Address:</b>	30 Technology Drive
<b>City:</b>	Warren
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07059
<b>Entity Type:</b>	Limited Liability Company: DELAWARE

**PROPERTY NUMBERS Total: 23**

Property Type	Number	Word Mark
<b>Serial Number:</b>	87719576	A
<b>Serial Number:</b>	87492329	LIBERVANT
<b>Serial Number:</b>	87163393	ALLERFILM
<b>Serial Number:</b>	87595759	EXORDIA
<b>Serial Number:</b>	87512075	EXSERVAN
<b>Serial Number:</b>	87492332	SYMPAZAN
<b>Serial Number:</b>	87458573	SSF

**TRADEMARK**

Property Type	Number	Word Mark
Serial Number:	87458567	OSF
Serial Number:	87458564	BSF
Serial Number:	87269501	DRUG DIFFERENTIATION BY DESIGN
Serial Number:	87163388	ANAFILM
Serial Number:	87163385	ANAPHYLM
Serial Number:	87163370	ANEPIFILM
Serial Number:	87163378	THEPIFILM
Serial Number:	87139551	PALLAQUEL
Serial Number:	87139549	EFFERVA
Serial Number:	87139547	CARESTA
Serial Number:	87139543	ASPONTA
Serial Number:	86662567	AQUESTIVE
Registration Number:	3877508	ZUPLENZ
Registration Number:	3349534	
Registration Number:	3336176	MONOSOL RX
Registration Number:	3580900	PHARMFILM

**CORRESPONDENCE DATA**

Fax Number: 2126983599

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 2126983500

Email: patents@dechert.com

Correspondent Name: Dechert LLP

Address Line 1: Three Bryant Park

Address Line 2: 1095 Avenue of the Americas, 26th Floor

Address Line 4: New York, NEW YORK 10036

<b>ATTORNEY DOCKET NUMBER:</b>	392874-166142
<b>NAME OF SUBMITTER:</b>	Michael Riego
<b>SIGNATURE:</b>	/Michael Riego/
<b>DATE SIGNED:</b>	07/15/2019

**Total Attachments: 3**

source=Aquestive - Termination to Trademark Security Agreement#page1.tif

source=Aquestive - Termination to Trademark Security Agreement#page2.tif

source=Aquestive - Termination to Trademark Security Agreement#page3.tif

**TERMINATION TO TRADEMARK SECURITY AGREEMENT**

This **TERMINATION TO TRADEMARK SECURITY AGREEMENT** (this "*Termination*"), dated as of July 15, 2019, is executed by PERCEPTIVE CREDIT HOLDINGS, LP ("*Collateral Agent*"), with an address at 51 Astor Place, 10th Floor, New York, NY 10003, in favor of AQUESTIVE THERAPEUTICS, INC., a Delaware corporation (f/k/a MonoSol Rx, LLC) ("*Grantor*"), MONOSOL RX, INC., a Delaware Corporation, and MSRX US, LLC, a Delaware limited liability company (collectively, "*Subsidiary Grantors*"), in each case, with an address at 30 Technology Drive, Warren, New Jersey, 07059.

**RECITALS**

**WHEREAS**, Grantor, Subsidiary Grantors and Collateral Agent entered into that certain Security Agreement, dated as of August 16, 2016 (as amended or otherwise modified from time to time, the "*Security Agreement*");

**WHEREAS**, in connection with the Security Agreement, Grantor, Subsidiary Grantors and Collateral Agent entered into that certain Trademark Security Agreement dated as of August 16, 2016 (as amended or otherwise modified from time to time, the "*Agreement*") pursuant to which Grantor and Subsidiary Grantors granted to Collateral Agent a security interest in the Trademark Collateral (as defined in the Agreement); and

**WHEREAS**, Collateral Agent has agreed to terminate and release its security interest in the Trademark Collateral as herein provided.

**NOW, THEREFORE**, in consideration of the foregoing, Collateral Agent agrees as follows:

1. Collateral Agent hereby terminates its security interest in the Trademark Collateral, including without limitation the trademarks listed on *Schedule 1* hereto, which security interest was evidenced by the recordation of the Security Agreement with the United States Patent and Trademark Office on August 17, 2016, in Reel/Frame 5857/0354 and January 30, 2018, in Reel/Frame 6261/0064.
2. Collateral Agent may record this Termination with the United States Patent and Trademark Office at the expense of Grantor.
3. Collateral Agent hereby authorizes Grantor or Grantor's agent to record this Termination with the United States Patent and Trademark Office and any other relevant governmental authority.
4. This Termination and the rights and obligations of the parties under this Termination shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

*[remainder of page intentionally left blank]*

IN WITNESS WHEREOF, Collateral Agent has executed this Termination on the date first written above.

**COLLATERAL AGENT:**

**PERCEPTIVE CREDIT HOLDINGS, LP, as  
Collateral Agent**

**By Perceptive Credit Opportunities GP, LLC, its  
general partner**



By:   
Name: Sandeep Dixit  
Title: Chief Credit Officer

By:   
Name: Sam Chawla  
Title: Portfolio Manager

**SCHEDULE 1**  
to the Termination to Trademark Security Agreement

**TRADEMARKS**

Trademark Registrations and Applications

Trademark	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
A Logo 	87719576	December 13, 2017	Aquestive Therapeutics, Inc.
LIBERVANT	87492329	June 16, 2017	Aquestive Therapeutics, Inc.
ALLERFILM	87163393	September 7, 2016	Aquestive Therapeutics, Inc.
EXORDIA	87595759	September 5, 2017	Aquestive Therapeutics, Inc.
EXSERVAN	87512075	June 30, 2017	Aquestive Therapeutics, Inc.
SYMPAZAN	87492332	June 16, 2017	Aquestive Therapeutics, Inc.
SSF	87458573	May 22, 2017	Aquestive Therapeutics, Inc.
OSF	87458567	May 22, 2017	Aquestive Therapeutics, Inc.
BSF	87458564	May 22, 2017	Aquestive Therapeutics, Inc.
DRUG DIFFERENTIATION BY DESIGN	87269501	December 15, 2016	Aquestive Therapeutics, Inc.
ANAFILM	87163388	September 7, 2016	Aquestive Therapeutics, Inc.
ANAPHYLM	87163385	September 7, 2016	Aquestive Therapeutics, Inc.
ANEPIFILM	87163370	September 7, 2016	Aquestive Therapeutics, Inc.
THEPIFILM	87163378	September 7, 2016	Aquestive Therapeutics, Inc.
PALLAQUEL	87139551	August 16, 2016	Aquestive Therapeutics, Inc.
EFFERVA	87139549	August 16, 2016	Aquestive Therapeutics, Inc.
CARESTA	87139547	August 16, 2016	Aquestive Therapeutics, Inc.
ASPONTA	87139543	August 16, 2016	Aquestive Therapeutics, Inc.
AQUESTIVE	86662567	June 15, 2015	Aquestive Therapeutics, Inc.
ZUPLENZ	3,877,508	November 16, 2010	Aquestive Therapeutics, Inc.
Miscellaneous Design 	3,349,534	December 4, 2007	Aquestive Therapeutics, Inc.
MONOSOL RX	3,336,176	November 13, 2007	Aquestive Therapeutics, Inc.
PHARMFILM	3,580,900	February 24, 2009	Aquestive Therapeutics, Inc.